1. Introduction {#S5}
===============

Obesity, a risk factor for the development of postmenopausal breast cancer and certain other cancer types, has also been associated with poorer response to cancer therapy and cancer recurrence ([@R38]). The increasing prevalence of obesity in the U.S. population, the independent association of obesity with cancer incidence, and the potential involvement of obesity in the recurrence of cancer have prompted interest in understanding the biological mechanisms that underlie obesity-cancer linkages ([@R42]). Obesity and physical inactivity are determinants of hyperinsulinema and insulin resistance ([@R15]), and obesity influences the amount of free insulin-like growth factor (IGF-I) available to cells ([@R9]). Hyerinsulinemia may be an underlying factor in chronic conditions such as type 2 diabetes mellitus, obesity, and certain forms of cancer, including breast cancer.

Weight gain and physical inactivity can occur following breast cancer treatment. For breast cancer survivors, cancer-related fatigue is a common symptom ([@R24]). Among women who have already been diagnosed with breast cancer, obesity is associated with breast cancer recurrence and poorer survival ([@R28]). Maintaining a healthy body weight reduces a woman's risk of cancer recurrence, diabetes and cardiovascular diseases ([@R39]).

In the U.S., breast cancer survival rates are lower among African American women than white women ([@R10]). Modifiable lifestyle factors related to energy balance and physical activity may contribute to this disparity. African American breast cancer survivors are less likely to report adherence to American Cancer Society recommendations for physical activity and nutrition ([@R22]).

In this commentary, we consider the literature on IGF, a mitogen in the mammary gland, and its binding proteins and risk of breast cancer. We also examine the roles played by obesity, adipokines secreted by adipose tissue, and insulin resistance on breast cancer carcinogenesis and the potential for lifestyle interventions to address weight gain and physical inactivity among at-risk women and breast cancer survivors, including African American women. We consider the interplay been these factors in influencing risk of breast cancer incidence and recurrence. Finally, we discuss remaining challenges in this area and offer suggestions for additional research.

2. Insulin-Like Growth Factor and Its Binding Proteins and Risk of Breast Cancer {#S6}
================================================================================

Development and differentiation of the normal mammary gland are dependent on the expression of locally produced growth factors (e.g., IGF-I) and systemically acting hormones. Two important factors involved in cellular and tissue function are the estrogen and insulin-like growth factor axes ([@R18]). The interaction of these pathways at transcriptional and translational levels regulates the expression and activity of genes involved in the development of the mammary gland. Estradiol, acting through estrogen receptors, is essential for the normal function of the mammary gland but can also promote the growth of breast cancer ([@R18]). Hence, regimens for the treatment of breast cancer commonly include selective estrogen receptor modulators, aromatase inhibitors, or selective estrogen receptor down-regulators. Breast tumors can develop resistance to anti-estrogen therapies, however, and other pathways (e.g., the IGF axis) are likely to be involved in breast cancer development and response to treatment. With respect to breast tumor development, experimental studies suggest that there appears to be a synergistic effect of estrogen receptor activation and increased IGF-I signaling ([@R20]).

Obesity influences the amount of free IGF-I available to cells, but is not a determinant of total IGF-I in the blood ([@R9]). Hyerinsulinemia is thought to be an underlying factor in breast cancer incidence. Higher insulin levels may contribute to increased tumor growth ([@R9]). Increases in circulating levels of IGF-I) have been observed in some epidemiologic studies of premenopausal breast cancer. IGF-I is an important mitogen in the mammary gland ([@R8]). When IGF-I binds to its cognate receptor (IGF-1R), it triggers a signaling cascade that leads to proliferative and anti-apoptotic events. The IGF-I system is involved in breast cancer development, progression, and metastasis ([@R8]).

The relationship between pre-diagnostic levels of IGF-I and IGF binding protein-3 (IGFBP-3) and breast cancer risk was examined in a meta-analysis of data from 17 prospective studies conducted in 12 countries ([@R14]). The overall odds ratio \[OR\] for breast cancer incidence was 1.28 (95% confidence interval \[CI\] 1.14-1.44). The positive association with IGF-I, which was not substantially modified by IGFBP-3 or by menopausal status, was limited to estrogen-receptor-positive breast cancers. Results from epidemiologic studies indicate that there are potentially modifiable determinants of circulating IGF-I concentrations including intake of dietary protein ([@R6]). [@R20]) conducted a case-control study of IGF-I and breast cancer incidence by age and hormone receptor status, nested within the prospective European EPIC cohort (938 breast cancer cases and 1,394 matched controls). IGF-I levels were positively associated with the risk of estrogen receptor-positive tumors overall (pre- and postmenopausal women combined, adjusted OR = 1.41, 95% CI 1.01-1.98 for the highest vs. lowest quartile) and among women who were diagnosed with breast cancer at 50 years or older (adjusted OR = 1.38, 95% CI 1.01-1.89), but not with receptor-positive disease diagnosed at an earlier age. No statistically significant associations were observed for estrogen receptor negative tumors overall or by age at diagnosis ([@R20]).

Although some studies have suggested that IGF-I is positively associated with risk of breast cancer incidence among premenopausal women, the results of epidemiologic studies have been inconsistent. [@R30] conducted a nested, case-control study of IGF-I, insulin-like binding protein-1 (IGFBP-1) and IGFBP-3 and breast cancer incidence in the Nurses Health Study II cohort, which mainly consists of premenopausal women. Plasma levels of IGF-I and its binding proteins were measured using prediagnostic samples obtained from 317 women diagnosed with invasive or in situ breast cancer and 634 matched controls. Overall, plasma levels of IGF-I, IGFBP-1 and IGFBP-3 were not associated with breast cancer risk. To examine the relationships between IGF-I and breast cancer incidence among premenopausal women, [@R29] conducted a pooled analysis of data from three prospective studies in New York; northern Sweden; and Milan, Italy. Statistically significant, positive associations were observed between IGF-I and IGFBP-3 and breast cancer risk among younger women.

Prognostic studies have shown that expression of IGF-1R, the receptor for IGF-I, is predictive of improved survival and that its expression is related to hormone receptor status ([@R43]; [@R32]). However, IGF-1R is a favorable prognostic indicator only in hormone receptor-positive breast cancers. IGF-1R positivity reflects a well-differentiated tumor with low metastatic tendency ([@R1]). Among women with triple-negative breast cancers, IGF-1R is a predictor of poorer survival ([@R19]). [@R19] examined the expression of proteins in the IGF axis and the association with breast cancer survival. In Native Hawaiian patients, IGFBP-2 and IGFBP-3 expression were each independently associated with overall and breast cancer mortality. IGF-1R expression was also positively associated with overall mortality in Native Hawaiians ([@R19]). In Japanese or Caucasian patients, however, no association of expression of IGF proteins and survival was observed.

3. Obesity, Adipokines, Insulin Resistance and Breast Cancer Carcinogenesis {#S7}
===========================================================================

Potential mechanisms linking obesity to higher cancer risk include obesity-related insulin resistance, hyperinsulinemia, hyperglycemia, glucose intolerance, and adipocytokine production ([@R5]). Adipose tissue secretes bioactive factors including estrogens and adipokines such as leptin and adiponectin, which mediate metabolism, angiogenesis, and cellular proliferation ([@R31]). Visceral fat is an active metabolic and endocrine tissue ([@R16]). Through the release of adipokines, adipose tissue influences several physiological functions, including appetite, satiety, energy expenditure, insulin sensitivity, and glucose and lipid metabolism ([@R3]). The hypertrophy of adipocytes and accumulation of excessive adipose tissue leads to dysregulation and alteration of peripheral tissue metabolism ([@R5]). Leptin secretion from adipose tissue is believed to promote breast cancer directly and independently and also through its effects on estrogen and insulin signaling pathways ([@R38]). Leptin promotes breast cancer progression through the activation of mitogenic, antiapoptotic, and metastatic pathways ([@R37]). Although leptin activates some carcinogenic pathways, adiponectin appears to have a regulatory role in insulin resistance and to exert antineoplastic activities and interfere with leptin-induced processes ([@R2]). Excess body fat is associated with increased expression of leptin and downregulation of adiponectin ([@R38]). The deregulation of adipokine signaling and altered adipokine hormone secretion from excess adipose is an area of active research into the mechanism and potential treatment (molecular targeting) of obesity-related cancer ([@R37]; [@R12]). In anti-obesity therapeutic interventions, adipokines have potential to be biomarkers of individual treatment success and disease progression ([@R3]).

Increased body weight and accumulation of central adiposity lead to changes in leptin and adiponectin levels and reduction of insulin sensitivity; weight loss improves insulin sensitivity and decreases risk for many potential complications of obesity ([@R16]). In a study of 90 obese women, a calorie-restricted diet and weight loss of \> 5% over a six-month period led to a reduction in leptin levels and an increase in adiponectin levels (p \< 0.001). Fasting glucose and insulin levels were also reduced in the research participants ([@R16]). Independent of weight loss, energy expenditure through exercise by improve leptin regulation ([@R31]).

1.3 Addressing Weight Gain and Physical Inactivity Among Breast Cancer Survivors {#S8}
--------------------------------------------------------------------------------

Physical activity and adopting a healthy diet are beneficial both in the general population and among breast cancer survivors ([@R22]). Among breast cancer survivors, a variety of approaches, including exercise and weight training, dietary interventions, yoga and mindfulness-based stress reduction, have addressed weight gain, fatigue, and other complaints. Considerable information exists about the effectiveness of such interventions for alleviating distress and improving quality of life among breast cancer survivors ([@R25]; [@R24]). Exercise (e.g., strength training, resistance training, walking, cycling, yoga, or Tai Chi) improves overall quality of life and cancer-related fatigue ([@R25]). A meta-analysis of 9 high-quality studies found that supervised aerobic exercise is more effective than conventional care in improving cancer-related fatigue among breast cancer survivors (standardized mean difference \[SMD\] = −0.51, 95% confidence interval \[CI\] −0.81 to −0.21) ([@R24]). Similar effects were found for resistance training on cancer related fatigue (SMD = −0.41, 95% CI −0.76 to −0.05).

In a meta-analysis of studies of breast cancer survivors, [@R23] found an inverse relationship between physical activity and all-cause, breast cancer-related death and breast cancer events, supporting the view that physical activity reduces death and breast cancer events among breast cancer survivors. Among older, overweight, and obese cancer survivors, physical activity and improved diet are positively associated with weight loss and higher physical functioning ([@R26]; [@R11]; [@R21]).

In the RENEW trial, which included survivors of breast, colorectal, and prostate cancer aged 65 to 91 years, a tailored intervention consisting of telephone counseling and mailed print materials on diet and exercise delivered over a 12-month period was effective in increasing exercise, improving diet, reducing weight, and increasing quality-of-life ([@R26]). Lifestyle interventions that focus on physical activity and improved diet reduce functional decline among older cancer survivors ([@R11]). Among the many randomized trials of physical activity and/or dietary interventions for breast cancer survivors, however, few have examined the maintenance of outcomes post-intervention, examined mediators of intervention effects, or focused on African American or Hispanic survivors ([@R34]; [@R33]).

African American breast cancer survivors are more likely to be obese and less likely to engage in physical activity than white survivors ([@R35]). In a study of 724 African American and 116 white breast cancer survivors, the African American survivors were more than twice as likely to have diminished physical functioning (odds ratio \[OR\] = 2.29, 95% CI 1.57, 3.34) ([@R35]). However, much of this disparity was due to racial differences in body mass index and other variables. A cross-sectional analysis of data from the 2009 Behavioral Risk Factor Surveillance System showed that African American breast cancer survivors were more likely to report obesity but less likely to report heavy alcohol consumption than their white counterparts (White et al. 2009). In a pilot study of 17 African American breast cancer survivors (stage 0 to IIIA) who were within 2 years of completing primary cancer treatments, in which the participants completed weekly exercise logs and received weekly motivational phone calls, a 16-week training program involving home-based aerobic and resistance physical activity improved cardiopulmonary fitness, strength, and functional movement ([@R35]). [@R17] completed a randomized controlled trial following 42 Hispanic and African American breast cancer survivors for 6 months in the commercially available Curves program, resulting in weight loss that was not maintained at 6 months post-intervention. The trial was limited by the small sample size, however. A community-based pilot study of walking ([@R41]), with 24 African American breast cancer survivors, resulted in increases in steps walked per day and decreases in body mass index, body weight and waist/hip circumferences, with most changes maintained at a 3-month follow-up. Stolley et al. (2009) used a pre-post design to test a 6-month intervention that included one of two weekly sessions dedicated to exercise; participants experienced significant changes in weight, body mass index, and social support. In a 16-week, home-based motivational exercise program for 13 African American breast cancer survivors, there was an increase in total minutes of physical activity post-intervention with improved physical functioning ([@R4]). In this population, larger-scale studies are needed to identify effective approaches to influence physical activity, nutrition, and achieve improvements in health-related quality-of-life.

4. Summary and Conclusions {#S9}
==========================

Epidemiologic studies indicate that greater body fatness is associated with a higher risk of certain cancers, including postmenopausal breast cancer and that the positive association may be partly explained, in part, by hyperinsulinemia and alterations in adipokines and estrogens ([@R27]). Considerable information exists about the effectiveness of interventions, such as exercise, weight training, dietary interventions, yoga and mindfulness-based stress reduction, for alleviating distress and improving quality of life among breast cancer survivors. Additional studies are needed to determine how to sustain the positive effects of exercise over time and to identify the optimal mode, intensity, frequency, duration, and timing of exercise for breast cancer survivors, including important subgroups such as African American and Hispanic women. Intervention studies on nutrition in these populations are also needed.

Nutrition, energy balance, and physical activity levels are important determinants of IGF-I bioactivity. Alterations in the IGF axis, related to physical activity and nutrition, can increase cancer risk and progression ([@R44]). This axis is involved in cellular growth, differentiation, proliferation regulation, and apoptosis. Results from epidemiologic studies indicate that higher circulating levels of IGF-I are associated with increased risk of breast cancer but do not support an association between IGFBP-1 and breast cancer. Although some epidemiologic studies support an association between IGFBP-3 and risk of breast cancer among younger women, results to date have been inconsistent. This inconsistency may be accounted for by differences in study design and lack of standardization across assays. IGFBP-3 regulates the bioavailability of IGF-I and is involved in breast cancer prognosis. Preliminary studies indicate that it may be possible to personalize dietary recommendations for breast cancer survivors based on IGF-I receptor status or other molecular characteristics of their tumor tissue ([@R13]).

There is increasing knowledge about the determinants of racial and ethnic disparities in breast cancer outcomes. It is likely that, in addition to a variety of social, structural, and environmental factors, biological factors influence how breast cancer is expressed ([@R10]). Alterations in IGF signaling induced by obesity and/or other factors may lead to these disparities ([@R19]). However, there is currently a paucity of health intervention studies that include sizeable numbers of African American or Hispanic breast cancer survivors. Future health intervention trials and epidemiologic studies of the relationships between the insulin-growth factor axis and breast cancer or breast cancer recurrence should include adequate numbers of African American, Hispanic, and non-Hispanic white women so that interactive effects by race and ethnicity can be more fully explored. Additional studies are also needed of American Indian, Alaska Native, Asian, and Pacific Islander women at-risk for breast cancer or for recurrence of the disease.
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